Pfizer Inc. (NYSE:PFE - Get Free Report)'s share price traded down 1.7% during mid-day trading on Friday after DZ Bank downgraded the stock from a buy rating to a hold rating. The stock traded as low as $28.54 and last traded at $29.3810. 48,156,994 shares were traded during trading, an increase of 21% from the average session volume of 39,871,961 shares. The stock had previously closed at $29.88.
Other equities research analysts have also issued research reports about the company. JPMorgan Chase & Co. raised their price target on Pfizer from $28.00 to $30.00 and gave the stock a "neutral" rating in a research report on Friday, October 9th. Argus set a $40.00 price objective on Pfizer in a research report on Wednesday. Weiss Ratings upgraded Pfizer from a "hold (c-)" rating to a "hold (c)" rating in a research report on Monday, August 31st. Bank of America lowered their target price on Pfizer from $27.00 to $26.00 and set a "neutral" rating for the company in a research note on Friday, July 10th. Finally, UBS Group raised their target price on shares of Pfizer from $27.00 to $30.00 and gave the stock a "neutral" rating in a report on Wednesday. Five equities research analysts have rated the stock with a Buy rating, thirteen have issued a Hold rating and two have assigned a Sell rating to the company's stock. Based on data from MarketBeat, the company currently has a consensus rating of "Hold" and an average price target of $30.18.
Check Out Our Latest Report on Pfizer
More Pfizer News
Here are the key news stories impacting Pfizer this week:
- Positive Sentiment: Guggenheim raised its price target to $33 from $31 and reiterated a Buy rating, signaling confidence in potential upside. Guggenheim rating
- Positive Sentiment: Pfizer’s latest quarterly report beat analyst estimates, and the company raised its 2026 revenue and earnings forecasts. That stronger outlook may help counter concerns about pressure on margins. Pfizer guidance update
- Neutral Sentiment: Pfizer updated notices for an ulcerative-colitis treatment-pattern study and a Phase 3 RSV vaccine study in high-risk children. The reports describe ongoing research, but do not provide results that establish a new efficacy or safety finding. Ulcerative colitis study update RSV vaccine study update
- Negative Sentiment: DZ Bank cut its rating on Pfizer from Buy to Hold, adding a cautious analyst signal. Pfizer also lagged as Moderna advanced after reporting an unexpected profit and raising its outlook, potentially drawing attention to competitive comparisons in the vaccine sector. DZ Bank rating Moderna earnings and peer trading
Institutional Trading of Pfizer
Hedge funds and other institutional investors have recently modified their holdings of the company. BlackRock Inc. increased its stake in shares of Pfizer by 6.3% in the second quarter. BlackRock Inc. now owns 529,670,433 shares of the biopharmaceutical company's stock worth $12,754,464,000 after buying an additional 31,412,883 shares during the period. State Street Corp raised its holdings in Pfizer by 1.8% during the 2nd quarter. State Street Corp now owns 307,090,897 shares of the biopharmaceutical company's stock valued at $7,394,749,000 after buying an additional 5,501,032 shares during the last quarter. Bank of New York Mellon Corp raised its holdings in Pfizer by 11.1% during the 1st quarter. Bank of New York Mellon Corp now owns 53,879,900 shares of the biopharmaceutical company's stock valued at $1,512,948,000 after buying an additional 5,364,929 shares during the last quarter. Bank of America Corp DE purchased a new stake in Pfizer during the 2nd quarter valued at $1,049,602,000. Finally, Dimensional Fund Advisors LP boosted its position in Pfizer by 0.8% during the 1st quarter. Dimensional Fund Advisors LP now owns 36,422,799 shares of the biopharmaceutical company's stock valued at $1,022,606,000 after buying an additional 293,029 shares during the period. Institutional investors and hedge funds own 68.36% of the company's stock.
Pfizer Stock Down 1.7%
The firm has a market cap of $167.46 billion, a PE ratio of 41.97, a PEG ratio of 2.04 and a beta of 0.31. The company has a debt-to-equity ratio of 0.67, a quick ratio of 0.96 and a current ratio of 1.42. The company's 50-day simple moving average is $28.72 and its two-hundred day simple moving average is $26.88.
Pfizer (NYSE:PFE - Get Free Report) last released its quarterly earnings data on Tuesday, November 3rd. The biopharmaceutical company reported $0.87 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $0.74 by $0.13. The firm had revenue of $16.58 billion for the quarter, compared to analysts' expectations of $15.85 billion. Pfizer had a net margin of 6.34% and a return on equity of 19.88%. The company's revenue for the quarter was down .4% compared to the same quarter last year. During the same quarter in the previous year, the company earned $0.87 earnings per share. On average, analysts predict that Pfizer Inc. will post 3.02 earnings per share for the current fiscal year.
Pfizer Dividend Announcement
The firm also recently declared a quarterly dividend, which will be paid on Monday, December 7th. Shareholders of record on Friday, November 6th will be given a dividend of $0.43 per share. The ex-dividend date of this dividend is Friday, November 6th. This represents a $1.72 dividend on an annualized basis and a yield of 5.9%. Pfizer's dividend payout ratio is presently 245.71%.
About Pfizer
(
Get Free Report)
Further Reading
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Pfizer, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Pfizer wasn't on the list.
While Pfizer currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Nuclear energy is entering a new growth cycle as rising power demand, expanding data centers, and renewed policy support bring the sector back into focus. After strong gains in recent years, the most impactful phase of nuclear investment may still be ahead. This report highlights seven nuclear energy stocks positioned across the value chain—combining near-term revenue with long-term upside as next-generation technologies scale. Click the link below to unlock the full list.
Get This Free Report
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Like this article? Share it with a colleague.
Link copied to clipboard.
